Global Media Strategies -- Your Brand, Your Audience

BioDelivery Sciences to Present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference

August 11, 2010 By: NCTechNews Category: Pharmaceuticals

(Raleigh, N.C.) BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that Dr. Mark A. Sirgo, President and Chief Executive Officer, will present at the Bank of America Merrill Lynch 2010 Specialty Pharmaceuticals Conference at the Southampton Inn in Southampton, New York. The presentation is scheduled for Friday, August 13 at 10:00 AM Eastern Time.

Dr. Sirgo will focus on BDSI’s product pipeline, including BEMA Buprenorphine for pain and opioid dependence, and BEMA Granisetron for the prevention of chemotherapy induced nausea and vomiting.

The presentation will be webcast live and can be accessed at www.bdsi.com. For those who are not available to listen to the live broadcast, the presentation will be archived through August 27, 2010.

About BioDelivery Sciences International

BioDelivery Sciences (NASDAQ: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics. BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care. BDSI’s pain franchise currently consists of two products utilizing the Company’s patented BEMA buccal soluble film technology. ONSOLIS (fentanyl buccal soluble film) was approved by FDA on July 16, 2009 for the management of breakthrough pain in patients with cancer, eighteen years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain. The commercial rights to ONSOLIS are licensed to Meda AB, who launched ONSOLIS in the U.S. last October, and Kunwha Pharmaceutical Co. Ltd. BDSI’s second pain product, BEMA Buprenorphine, just completed Phase 2 clinical development for the treatment of chronic pain, and in a higher dose formulation for the treatment of opioid dependence. Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA “Triptan”). BDSI’s headquarters is located in Raleigh, North Carolina. For more information please visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc. ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.

Comments are closed.

← ChannelAdvisor Announces Support for Amazon France and Germany
FM:Systems Launches New BIM Integration and Sustainability Module →

  • Packaging Cures
    RTP-based advertising and branding firm The Marketing Machine helped overcome the issue of illiteracy among medical patients in Ghana, South Africa in designing packaging for the only manufacturer of anti-retroviral drugs in the region, creating individual icons and colors to help patients understand which drugs they needed, regardless of their ability to read.

    Broadband Stimulus
    Two grants funded by the American Recovery and Reinvestment Act are being used by MCNC to expand broadband connectivity and services throughout North Carolina and create more than 1,000 engineering and construction jobs, the organization said.

    Video: QC in Pharma Mfg


    Defense Industry Gets More Competitive
    U.S. troop level decreases and shrinking armed forces budgets will lead to increased competition and a change in business operations for military contractors in North Carolina and throughout the nation, according to defense industry contracting expert Lea Strickland, requiring a more strategic and tactical approach to developing professional, properly-designed bid proposals.

    A Leg Up for Students
    Innovative concept-to-marketplace product design and development firm Montie Design is holding a Winter 2012 Student Design Contest for aspiring product designers in community colleges, four-year colleges, or high schools from North Carolina and Virginia, starting February 1.

    getting from lab 2 line
    The leader in analytical instrumentation for the pharma manufacturing industry has named a new COO responsible for manufacturing, engineering, software development, and project management for hardware and software products such as the VTT-1000 multi-variant testing device, breaking down barriers to speeding-up the drug manufacturing pipeline and cutting-down on drug shortages.

  • Recent Headlines

















free web site traffic and promotion